Last $0.39 USD
Change Today +0.001 / 0.26%
Volume 46.1K
CMXI On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

cytomedix inc (CMXI) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/4/13 - $0.68
52 Week Low
11/13/13 - $0.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CYTOMEDIX INC (CMXI)

Related News

No related news articles were found.

cytomedix inc (CMXI) Related Businessweek News

No Related Businessweek News Found

cytomedix inc (CMXI) Details

Cytomedix, Inc. operates as a regenerative therapies company in the United States and internationally. The company manufactures and distributes the AutoloGel System, a point of care device for the production of a platelet based bioactive therapy derived from the patient’s own blood; and Angel Concentrated Platelet Rich Plasma System, a multi-functional cell separation device, which produces concentrated platelet rich plasma for use in the operating room and clinic, as well as in a range of orthopedic and cardiovascular indications. Its Angel product line also includes ancillary products, such as phlebotomy and applicator supplies; and activAT, which produces autologous thrombin serum from platelet poor plasma. Cytomedix, Inc. sells its products through direct sales representatives and distributors. The company was formerly known as Autologous Wound Therapy, Inc. and changed its name to Cytomedix, Inc. in 2000. Cytomedix, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

40 Employees
Last Reported Date: 05/15/14
Founded in 1987

cytomedix inc (CMXI) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $467.3K
Executive Chairman
Total Annual Compensation: $100.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $185.3K
Compensation as of Fiscal Year 2013.

cytomedix inc (CMXI) Key Developments

Cytomedix, Inc. Approves Amendments to Certificate of Incorporation

The Special Meeting of shareholders of Cytomedix, Inc. was held on June 9, 2014. At the meeting, the shareholders approved an amendment to the company's Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 425,000,000 and the number of authorized shares of capital stock from 215,000,000 to 440,000,000 and approved an amendment to the company's Certification of Incorporation to effect a reverse stock split of the authorized and outstanding shares of the company's common stock.

Cytomedix, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Cytomedix, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported total revenues of $1.8 million compared to $2.3 million in the same period of 2013. The decrease was primarily due to lower product sales of $0.8 million offset by an increase in royalty revenue of $0.3 million and license fee revenue of $0.1 million. Net loss was $5.6 million, or a loss of $0.05 per basic share compared to a net loss of $5.3 million, or a $0.05 loss per basic share in the first quarter of 2013. Loss from operations was $4,650,160 compared to $5,003,210 a year ago. Net loss before provision for income taxes was $5,628,268 compared to $5,333,679 a year ago.

Cytomedix, Inc. to Report Q1, 2014 Results on May 15, 2014

Cytomedix, Inc. announced that they will report Q1, 2014 results at 5:00 PM, Eastern Standard Time on May 15, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CMXI:US $0.39 USD +0.001

CMXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aastrom Biosciences Inc $3.61 USD -0.02
Athersys Inc $1.71 USD +0.02
Cesca Therapeutics Inc $1.34 USD +0.02
Cytori Therapeutics Inc $2.22 USD +0.01
Pluristem Therapeutics Inc $2.95 USD +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation CMXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.9x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTOMEDIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at